We are live on ! Find out more
TPST icon

Tempest Therapeutics

53 hedge funds and large institutions have $244M invested in Tempest Therapeutics in 2014 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 12 increasing their positions, 7 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

550% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 2

90% more capital invested

Capital invested by funds: $129M → $244M (+$115M)

71% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 7

26% more funds holding

Funds holding: 4253 (+11)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
53
Holders Change
+11
Holders Change %
+26.19%
% of All Funds
1.54%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
13
Increased
12
Reduced
7
Closed
2
Calls
Puts
Net Calls
Net Calls Change

TPST Hedge Fund Activity: Q3 2014 in Review

53 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q3 2014, worth a combined $244M — up 90% from $129M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new TPST positions and 2 closed out — a net gain of 11 holders — while 12 added to existing stakes and 7 trimmed.

The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $6.17M. The largest seller was Deerfield Management, cutting an estimated $6.17M.

  • 53 institutional investors held Tempest Therapeutics (TPST) as of Q3 2014, up from 42 in Q2 2014.
  • Funds reported $244M of Tempest Therapeutics stock for Q3 2014, up 90% quarter-over-quarter.
  • 13 funds opened new Tempest Therapeutics positions in Q3 2014 and 2 closed out, a net change of +11 holders.
  • The largest Tempest Therapeutics buyer in Q3 2014 was Cormorant Asset Management, an estimated $6.17M added.
  • The largest Tempest Therapeutics seller in Q3 2014 was Deerfield Management, an estimated $6.17M sold.

Based on aggregated 13F filings for Q3 2014.